Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040742 · ClinicalTrials.gov registry record · Phase 2
Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer
A Phase 2 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 2
- Development phase
- 745
- Enrollment target
NCT00040742: Completed Phase 2 study, sponsored by Gary Morrow.
NCT00040742 is a Phase 2 study that has completed, run by Gary Morrow. The registered enrollment target is 745 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (460% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040742, a Phase 2 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 745 participants
- Enrollment target
Study Summary
RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy. PURPOSE: This randomized phase II/III trial is studying giving antiemetic drugs together with ginger to see how well they work compared to antiemetic drugs alone in treating nausea in patients who are receiving chemotherapy for cancer.
Primary Outcome
Nausea evaluated on a 7-point semantic rating scale anchored by "1" = "Not at all nauseated" and by "7" = "Extremely nauseated." Acute nausea calculated as the maximum of the Day 1 Evening and Night nausea ratings. Change from post-intervention (cycle 2 of chemotherapy) - baseline (cycle 1 of chemotherapy) of peak acute nausea used as the outcome measure. Negative values for this outcome are favorable.
Interventions
- OTHER placebo
- DIETARY_SUPPLEMENT ginger
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 745 participants |
| Start Date | 2003-03 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT00040742 record still lists
NCT00040742 is an interventional study that assigns participants to a tested intervention. The registered 745 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (460% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00040742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040742 about?
NCT00040742 is a clinical study titled "Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer". RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy. PURPOSE: This randomized phase II/III trial is studying giving antiemetic drugs together with ginger to see how well they...
What is the current status of trial NCT00040742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 745 participants. The study started on 2003-03. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00040742?
The interventions under investigation include: placebo (OTHER), ginger (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00040742?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00040742's enrollment target sits among peer trials
745 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia